Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years' follow-up in first-line advanced renal cell carcinoma

Prensa/medios de comunicación

Período16 feb. 2023

Cobertura de los medios

1

Cobertura de los medios

  • NombreCabometyx® in combination with nivolumab shows durable survival benefits at over three-years' follow-up in first-line advanced renal cell carcinoma
    Nombre/canal del medio de comunicaciónIndian Pharma Industry : Policies
    País/TerritorioIndia
    Fecha16/02/23
    PersonasMauricio Burotto